美国 · 股市与财经 · Quartz
FDA advisers are voting on Grail's multicancer blood test as Medicare coverage hangs in the balance
The Molecular and Clinical Genetics Panel is weighing the Galleri test's clinical evidence today; Medicare coverage could follow FDA approval
在 Quartz 阅读全文 登录后可收藏MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (qz.com)
